Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GO 17A3 - Bispecific antibody - GO Therapeutics

Drug Profile

GO 17A3 - Bispecific antibody - GO Therapeutics

Alternative Names: GO-17A3 - T cell bispecific therapeutic - GO Therapeutics; GO17A3 TCB therapeutic - GO Therapeutics

Latest Information Update: 04 Feb 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GO Therapeutics
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Malignant melanoma; Sarcoma

Most Recent Events

  • 22 Jan 2021 Early research in Malignant melanoma in USA (Parenteral) before January 2021 (GO Therapeutics pipeline, January 2021)
  • 22 Jan 2021 Early research in Sarcoma in USA (Parenteral) before January 2021 (GO Therapeutics pipeline, January 2021)
  • 19 Jan 2021 GO 17A3 - GO Therapeutics is available for licensing as of 22 Jan 2021. https://gotherapeutics.com/partnerships/
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top